Article Text

Download PDFPDF
Cardiovascular highlights from non-cardiology journals
  1. Shannon McConnaughey1,
  2. James McCabe2
  1. 1 Department of Medicine, University of Washington, Seattle, Washington, USA
  2. 2 Division of Cardiology, University of Washington, Seattle, Washington, USA
  1. Correspondence to Dr James McCabe; jmmccabe{at}cardiology.washington.edu

Statistics from Altmetric.com

Rivaroxaban plus aspirin for secondary prevention in stable cardiovascular disease

Five to 10% of patients with cardiovascular disease have recurrent events each year. Despite evidence in support of adding warfarin to antiplatelet agents for secondary prevention among at-risk patients, the countervailing bleeding risks have limited adoption in clinical practice. Given the potentially favourable risk profile of direct oral anticoagulants compared with warfarin, these agents have generated interest as potential adjunctive therapy for secondary cardiovascular prevention. The Cardiovascular …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.